Roy Baynes

Dr. Roy D.
Baynes is an Independent Director at Nurix Therapeutics, Inc., an Independent Non-Executive Director at ADCendo ApS, an Independent Director at Aardvark Therapeutics, Inc., a Chief Medical Officer & Executive Vice President at Eikon Therapeutics, Inc., an Independent Director at Natera, Inc., an Independent Director at Travere Therapeutics, Inc., a Member at American Association for Cancer Research, a Member at American Society of Clinical Oncology, Inc. and a Member at American Society of Hematology.
He is on the Board of Directors at Nurix Therapeutics, Inc., ADCendo ApS, Aardvark Therapeutics, Inc., CatalYm GmbH, Natera, Inc. and Travere Therapeutics, Inc. Dr. Baynes was previously employed as an Independent Director by Atara Biotherapeutics, Inc., a Chief Medical Officer by Merck & Co., Inc., a Chief Medical Officer by Merck Research Laboratories Massachusetts LLC, a SVP-Oncology, Inflammation & Respiratory by Gilead Sciences, Inc., a VP-Global Development & Head-Hematology Oncology by Amgen, Inc., and a Professor by Barbara Ann Karmanos Cancer Institute.
He received his graduate degree from the University of the Witwatersrand and a doctorate degree from the University of the Witwatersrand.